Clinical trial Recruiting at 1 site Observational Ages 18 to 99

Observational study of patients with systemic amyloidosis

Official title: Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis

Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06866912 · Data updated 2026-11-12

This study looks at patients with systemic amyloidosis, especially those with heart issues, to learn more about their experiences and outcomes.

Quick facts

Study typeObservational
Ages18 Years to 99 Years
SexAll
Enrollment750 (estimated)
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
Academic / other
Locations1 site (Bologna)
StatusRecruiting
StartedSeptember 1, 2023
Main results expectedAugust 31, 2033
Study endsAugust 31, 2033
Registry record updatedMarch 10, 2025
Trial IDNCT06866912 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older diagnosed with amyloidosis or asymptomatic carriers of transthyretin gene mutations.

Probably not a fit

Patients who do not have amyloidosis or are under 18 years old may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational epidemiological study focuses on patients diagnosed with systemic amyloidosis, particularly those with cardiac involvement. It aims to gather data on the characteristics and outcomes of these patients to better understand the disease's impact. The study will include both symptomatic patients and asymptomatic carriers of mutations in the transthyretin gene, allowing for a comprehensive analysis of the condition. Participants will be recruited from a single institution in Bologna, Italy.

Why it matters

Potential benefit: If successful, this study could enhance understanding of systemic amyloidosis and improve patient management strategies.

How similar studies have gone: While observational studies on amyloidosis exist, this specific approach focusing on systemic amyloidosis and its cardiac implications may provide novel insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* patients diagnosed with amyloidosis or asymptomatic carriers of mutations in the transthyretin gene
* minimum age of 18 years at the time of diagnosis
* obtaining informed consent

Exclusion Criteria:

* nothing

Where it's running

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna
    Bologna, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.